Understanding these mechanisms reveals actionable therapeutic targets, including inhibition of PSGL-1/P-selectin interactions and blockade of caspase-1–mediated pyroptosis, offering potential strategies to restore CD8+ T cell functionality and disrupt persistent inflammation in ITP. Here, CD8A is linked to autoimmune thrombocytopenic purpura.